Evidence map›Paper›PMID 39501994›Full record

Observational studyInternational health2025

Supporting multidrug-resistant or rifampicin-resistant TB treatment adherence in people with harmful use of alcohol through person-centred care.

Rebecca E Harrison, Volha Shyleika, Raman Vishneuski, Olga Leonovich, Dmitri Vetushko, Alena Skrahina, Htay Thet Mar, Ekaterine Garsevanidze, Christian Falkenstein, Öznur Sayakci and 8 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rebecca E HarrisonMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Volha ShyleikaMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Raman VishneuskiMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Olga LeonovichMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Dmitri VetushkoClinical Department, Republican Scientific and Practical Centre of Pulmonology and Tuberculosis (RSPCPT), Minsk 220053, Belarus.
Alena SkrahinaClinical Department, Republican Scientific and Practical Centre of Pulmonology and Tuberculosis (RSPCPT), Minsk 220053, Belarus.
Htay Thet MarMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Ekaterine GarsevanidzeMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Christian FalkensteinMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Öznur SayakciMedical Department, Médecins Sans Frontières, Minsk 220053, Belarus.
Antonio Isidro Carrion MartinManson Unit, Médecins Sans Frontières, London EC4A 1AB, UK.
Cecilio TanMedical Department, Médecins Sans Frontières, Moscow 127006, Russia.
Norman SitaliMedical Department, Médecins Sans Frontières, Berlin 13359, Germany.
Kerri VineyDept of Global Public Health, Karolinska Institutet, Stockholm SE-17177, Sweden.ORCID 0000-0002-0453-4339
Knut LonnrothDept of Global Public Health, Karolinska Institutet, Stockholm SE-17177, Sweden.
Beverley StringerManson Unit, Médecins Sans Frontières, London EC4A 1AB, UK.
Cono AritiManson Unit, Médecins Sans Frontières, London EC4A 1AB, UK.
Animesh SinhaManson Unit, Médecins Sans Frontières, London EC4A 1AB, UK.ORCID 0000-0003-3213-7813

Funding

Medecins Sans FrontieresWorld Health Organization 001
6 · The paper itself

Abstract

backgroundTB is concentrated in populations with complex health and social issues, including alcohol use disorders (AUD). We describe treatment adherence and outcomes in a person-centred, multidisciplinary, psychosocial support and harm reduction intervention for people with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) with harmful alcohol use.

methodsAn observational cohort study, including multilevel mixed-effects logistic regression and survival analysis with people living in Minsk admitted with MDR/RR-TB and AUD during January 2019-November 2021 who received this person-centred, multidisciplinary, psychosocial support and harm reduction intervention, was conducted.

resultsThere were 89 participants enrolled in the intervention, with a median follow-up of 12.2 (IQR: 8.1-20.5) mo. The majority (n=80; 89.9%) of participants had AUD, 11 (12.4%) also had a dependence on other substances, six (6.7%) a dependence on opioids and three (3.4%) a personality disorder. Fifty-eight had a history of past incarceration (65.2%), homelessness (n=9; 10.1%) or unemployment (n=55; 61.8%). Median adherence was 95.4% (IQR: 90.4-99.6%) and outpatient adherence was 91.2% (IQR: 65.1-97.0%). Lower adherence was associated with hepatitis C, alcohol plus other substance use and outpatient facility-based treatment, rather than video-observed treatment, home-based or inpatient treatment support.

conclusionsThis intervention led to good adherence to MDR/RR-TB treatment in people with harmful use of alcohol, a group usually at risk of poor outcomes. Poor outcomes were associated with hepatitis C, other substance misuse and outpatient facility-based treatment support.

Indexed as

AlcoholismAntitubercular AgentsPatient-Centered CareTreatment Adherence and ComplianceTuberculosis, Multidrug-ResistantAdultCohort StudiesFemaleHarm ReductionHumansMaleMiddle AgedRifampinAntitubercular AgentsRifampinalcohol use disorderdirectly observed treatmentMDR/RR-TBmultidisciplinarypsychosocial caretreatment support

Identifiers

PMID39501994
PMCPMC12045086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.